Compugen LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ

2 Mar 2026

CGEN

Compugen LTD

20-F: Compugen Reports 2025 Profit, Advances Immuno-Oncology Pipeline

Compugen Ltd. reported a net profit of $35.3 million in 2025, driven by significant upfront and milestone payments from strategic partnerships, while advancing its clinical-stage immuno-oncology programs.

NASDAQ

4 Mar 2025

CGEN

Compugen LTD

20-F: Compugen Ltd. Files 20-F Report, CGEN Stock Remains Steady

Compugen Ltd. released its annual report on Form 20-F, detailing the company's financial performance and operational activities for the fiscal year ended December 31, 2024.

NASDAQ

5 Mar 2024

CGEN

Compugen LTD

20-F: Compugen Inks Exclusive Licensing Deal with Gilead for Novel Immunotherapy Program, COM503

Compugen grants Gilead exclusive rights to its preclinical antibody program targeting IL-18 binding protein, including COM503, for a potential $848 million deal.